Clinical Relevance of Prognostic Factors in Axillary Node-Negative Breast Cancer
暂无分享,去创建一个
[1] R. Gelber,et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Fernö,et al. Expression of cyclins E, A, and B, and prognosis in lymph node‐negative breast cancer , 2003, The Journal of pathology.
[3] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[4] Isabelle Bedrosian,et al. Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.
[5] M. Kiechle,et al. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. , 2002, Clinical breast cancer.
[6] D. Amadori,et al. Quality Control for Biomarker Determination in Oncology: The Experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT) , 2002, The International journal of biological markers.
[7] H. Junkermann,et al. [Evidence-based recommendations on primary treatment of carcinomas of the breast]. , 2002, Zentralblatt fur Gynakologie.
[8] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[9] N. Brünner,et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. , 2002, Journal of the National Cancer Institute.
[10] K. Pantel,et al. Occult micrometastasis: enrichment, identification and characterization of single disseminated tumour cells. , 2001, Seminars in cancer biology.
[11] A. Paradiso,et al. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Mollianne J. McGahren,et al. Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms , 2001, Molecular and Cellular Biology.
[13] C. Sweep,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.
[14] O. Nanni,et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study , 2000, Breast Cancer Research and Treatment.
[15] O. Nanni,et al. Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Mike Clarke,et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years , 2000, The Lancet.
[17] T. Dimpfl,et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.
[18] F. Jänicke,et al. Do we need better prognostic factors in node-negative breast cancer? Pro:. , 2000, European journal of cancer.
[19] M G Daidone,et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer , 1999, International journal of cancer.
[20] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[21] H. Höfler,et al. Invasion marker PAI‐1 remains a strong prognostic factor after long‐term follow‐up both for primary breast cancer and following first relapse , 1999, Breast Cancer Research and Treatment.
[22] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[23] M. Skobe,et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.
[24] I. Funke,et al. Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[26] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[27] M. Daidone,et al. Cell proliferation in 3,800 node‐negative breast cancers: Concistency over time of biological and clinical information provided by 3H‐Thymidine labelling index , 1997, International journal of cancer.
[28] D. Bortner,et al. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.
[29] S. Braun,et al. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.
[30] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[31] Steingrimur Stefansson,et al. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin , 1996, Nature.
[32] S. Hilsenbeck,et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] H. Allgayer,et al. Individual development and uPA–receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer , 1995, Nature Medicine.
[34] James M. Roberts,et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition , 1995, Molecular and cellular biology.
[35] U. Veronesi,et al. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] K. Ulm,et al. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. , 1994, Cancer research.
[37] W. Eiermann,et al. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. , 1994, British Journal of Cancer.
[38] K. Keyomarsi,et al. Redundant cyclin overexpression and gene amplification in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Winstanley,et al. Long-term prognostic significance of thymidine labelling index in primary breast cancer. , 1992, European journal of cancer.
[40] F. Clayton. Pathologic correlates of survival in 378 lymph node‐negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor , 1991, Cancer.
[41] G M Clark,et al. How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.
[42] M. Fernö,et al. Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.
[43] S. Koscielny,et al. Growth rate, kinetics of tumor cell proliferation and long‐term outcome in human breast cancer , 1989, International journal of cancer.
[44] R. Coombes,et al. The fate of bone marrow micrometastases in patients with primary breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M Héry,et al. Factors affecting relapse in node-negative breast cancer. A multivariate analysis including the labeling index. , 1989, European journal of cancer & clinical oncology.
[46] M. Duffy,et al. Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.
[47] M. Daidone,et al. Cell kinetics as a prognostic marker in node‐negative breast cancer , 1985, Cancer.
[48] H. Skipper,et al. Kinetics of mammary tumor cell growth and implications for therapy , 1971, Cancer.
[49] H. Höfler,et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer , 2005, Breast Cancer Research and Treatment.
[50] N. Harbeck,et al. Minimal residual disease in breast cancer and gynecological malignancies: phenotype and clinical relevance. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[51] Van,et al. A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.
[52] I. Kleinschmidt,et al. Cyclin E immunoexpression in breast ductal carcinoma: pathologic correlations and prognostic implications. , 2001, Human pathology.
[53] H Sommer,et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] G. Clark,et al. S-phase fraction and breast cancer - a decade of experience , 1998, Breast Cancer Research and Treatment.
[55] N. Harbeck,et al. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer. , 1997, British Journal of Cancer.
[56] K. Keyomarsi,et al. The role of cyclin E in cell proliferation, development and cancer. , 1997, Progress in cell cycle research.
[57] R. Holle,et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.